electroCore, Inc. (ECOR)

Market Cap	35.29M
Revenue (ttm)	13.40M
Net Income (ttm)	-20.59M
Shares Out	6.00M
EPS (ttm)	-4.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,514
Open	5.59
Previous Close	5.62
Day's Range	5.59 - 5.95
52-Week Range	3.10 - 7.50
Beta	1.00
Analysts	Strong Buy
Price Target	14.88 (+153.06%)
Earnings Date	Nov 8, 2023

About ECOR

electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults; Truvaga for the support of general health and wellbeing; and TAC-STIM, a form of nVNS for human performance. Its lead product is gammaCore Sapphire, a rechargeable and reloadable ha...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 22, 2018
• Employees: 62
• Stock Exchange: NASDAQ
• Ticker Symbol: ECOR

Financial Performance

In 2022, electroCore's revenue was $8.59 million, an increase of 57.62% compared to the previous year's $5.45 million. Losses were -$22.16 million, 28.7% more than in 2021.

Analyst Forecast

According to 2 analysts, the average rating for ECOR stock is "Strong Buy." The 12-month stock price forecast is $14.88, which is an increase of 153.06% from the latest price.

Price Target

$14.88

(153.06% upside)

Analyst Consensus: Strong Buy